English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The impact of pharmacogenetics on predicting survival in diffuse large B-cell lymphoma (DLBCL) remains unclear. We tested 337 DLBCL patients treated with rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for 9 single nucleotide polymorphisms from 6 genes ( CD20 ,  FCGR2A ,  NAD(P)H, ABCC2 ,  ABCG2  and  CYP3A5 ). Patients who carried the  NCF4  rs1883112 GG genotype showed significantly shorter progression-free survival (PFS) ( P  = 0.023) and event-free survival (EFS) ( P  < 0.001) comparing with A allele. A significantly shortened PFS ( P  = 0.013) and EFS ( P  = 0.002) was also observed in the patients with  ABCG2  rs2231137 GG genotype. Furthermore, the elder (> 60 years old) or male patients with  ABCG2  rs2231137 GG genotype had poorer PFS and EFS than A allele. Moreover,  CD20  rs2070770 CC and  RAC2  rs13058338 AT genotypes were independent predictors of chemotherapy-induced toxicity. Cox proportional hazards analyses demonstrated that the GG genotype of  ABCG2  rs2231137 and  NCF4  rs1883112 were risk factors in DLBCL patients. In conclusion, the identified polymorphisms provide guide for the identification of DLBCL patients who are likely to benefit from chemotherapy.

ABCG2 and NCF4 polymorphisms are associated with clinical outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP